CAR-T疗法在血液病中的临床应用研究进展

Clinical application of CAR-T therapy in hematology

嵌合抗原受体T细胞(CAR-T)是一种新型细胞免疫治疗方法,其通过基因编辑技术将针对特定靶点的嵌合抗原受体以及共刺激分子引入T细胞之中,特异性地识别恶性肿瘤细胞,最终将其杀灭。CAR-T细胞疗法在血液病治疗领域开辟了崭新的途径,目前治疗领域包括复发难治B细胞淋巴瘤/白血病、慢性髓系白血病、多发性骨髓瘤等,并在实体肿瘤治疗中初见成效。细胞因子释放综合征、神经系统毒副反应、感染风险增加及治疗相关死亡率是其主要不良事件。CAR-T细胞技术是血液病治疗发展的里程碑事件,不断取得新的突破,值得关注与研究。

Chimeric antigen receptor T cell( CAR-T) is a new method of cell immunotherapy. Through gene editing technology,the chimeric antigen receptor and co-stimulator are introduced into T cells to identify malignant tumor cells specifically,and eventually kill them. CAR-T cell therapy has opened up a new way for the treatment of hematological diseases. It has been applied to the treatment of diseased including relapse refractory B cell lymphoma/leukemia,chronic myeloid leukemia,multiple myeloma and so on,and it has also been effective in the treatment of solid tumors. Cytokine release syndrome,neurological side effects,increased risk of infection and treatment-related mortality are the major adverse events. CAR-T cell therapy is a rising star in the field of hematology treatment. It deserves our attention and research.